News
Sarepta Therapeutics (SRPT) shares fell as much as 4.8% in premarket trading Monday, poised to extend losses for a second ...
The ground shook for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) last week as the U.S. Food and Drug Administration (FDA), ...
Sarepta Therapeutics faces challenges as the FDA halts gene therapy trials for LGMD and revokes AAVrh74 platform designation.
Julie Hyman outlines some of the top stories on Wall Street as part of Monday, July 21's Market Minute. Navitas (NVTS) stock ...
2h
InvestorsHub on MSNSarepta Shares Drop as FDA Suspends Gene Therapy Trials for Muscular DystrophyShares of Sarepta Therapeutics Inc (NASDAQ:SRPT) plunged 10% after the company disclosed that the U.S. Food and Drug ...
Investing.com -- Sarepta Therapeutics Inc (NASDAQ: SRPT) stock tumbled 10% following the announcement that the U.S. Food and Drug Administration has placed a clinical hold on the company’s ...
US stocks rose on Monday, with fresh records for the Nasdaq Composite (^IXIC) and S&P 500 (^GSPC) in sight as Wall Street ...
The Dow Jones Industrial Average was up 233 points, or 0.5%, as of 12:51 p.m. Eastern time, and the Nasdaq composite was adding 0.7 ... That helped offset a 4.2% drop for Sarepta Therapeutics, which ...
Block Inc. shares jumped 9% in premarket following news late Friday that the parent company of Square [will join the S&P 500 this week]( ...
1h
Barchart on MSNS&P 500 and Nasdaq 100 Jump to Record Highs as Bond Yields FallThe S&P 500 Index ($SPX) (SPY) today is up +0.54%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.41%, and the Nasdaq ...
New board members bring decades of experience in company building, corporate strategy, commercialization, and business development CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results